Hepatitis C virus and liver transplantation

Area of Science:

• Hepatology
• Transplantation Immunology
• Virology

Background:

• Hepatitis C virus (HCV) is a leading cause for liver transplantation in Europe and North America.
• While short-term outcomes are favorable, HCV recurrence post-transplant is frequent.
• Long-term follow-up reveals increasing rates of fibrosis, cirrhosis, and graft loss due to recurrent HCV.

Purpose of the Study:

• To evaluate the long-term outcomes of liver transplantation in HCV-infected patients.
• To identify factors influencing disease progression after HCV recurrence.
• To review current and emerging therapies for post-transplant HCV.

Main Methods:

• Analysis of patient and graft survival data in HCV-infected liver transplant recipients.
• Investigation of viral and host factors associated with fibrosis and cirrhosis progression.
• Review of clinical trial data for antiviral therapies in post-transplant HCV.

Main Results:

• Five-year survival rates for patients and grafts are comparable to those undergoing transplantation for other chronic liver diseases.
• Progressive fibrosis, cirrhosis, and graft loss due to recurrent HCV increase with longer follow-up periods.
• Both viral and host factors contribute to the risk of disease progression.

Conclusions:

• Liver transplantation offers similar short-term survival for HCV patients compared to other indications.
• Long-term management of recurrent HCV is critical to prevent graft loss.
• Combined interferon and ribavirin show promise as a therapeutic strategy for post-transplant HCV.